Table 1 Overview of the characteristics of the studies included in the systematic review.
Study | TS: N, (mean age ± SD); N females (f) | Controls: N, (mean age ± SD); N females (f) | Controls’ diagnosis | Assessment (time) | HRV outcome measures | Psychological outcome measures | Significant findings | NOS score |
|---|---|---|---|---|---|---|---|---|
Akashi et al., 2007*42 | 10 (70.1 ± 13.7); 8 f. | 10 (70.0 ± 6.1); not defined | HV | 2 ± 1 days after admission (0 months) and 3.0 ± 0.2 months after discharge (3 months) | Mean RR; SDNN; SDANN; pNN50; RMSSD; LF; HF; TF; LF/HF | None | SDNN: TS 0 months < HV (p = 0.007); TS 0 months < TS 3 months (p = 0.01) SDANN: TS 0 months < HV (p = 0.01); TS 0 months < TS 3 months (p = 0.03) TF: TS 0 months < HV (p = 0.005) LF: TS 0 months < HV (p = 0.01); TS 3 months < HV (p = 0.02) LF/HF: TS 3 months < HV (p = 0.006) | 9 |
Bonnemeier et al., 2010**45 | 27 (68.6 ± 11); 26 f. | 10 (64.5 ± 8); 10 f. | MB | Third day after hospital admission | Mean RR; SDNN; SDANN; RMSSD; LF; HF; LF/HF; 1/f PLS; ApEn; AC; DC | None | SDANN: TS > MB (p = 0.029) LF: TS < MB (p = 0.028) HF: TS > MB (p = 0.034) LF/HF: TS < MB (p = 0.031) 1/f PLS: TS < MB (p = 0.008) ApEn: TS > MB (p = 0.009) AC: TS < MB (p = 0.005) DC: TS > MB (p = 0.004) | 7 |
Collste et al., 2014*48 | 22 (63.2); 21 f. | 22 (63.6); 21 f. | HV | 6 months after the acute event | SDNN; SDANN | Mental Stress Test | SDNN pre-stress Δ: TS > HV (p = 0.002) | 7 |
Krstacic et al., 2012*41 | 25 (60.2 ± 8.3); 25 f. | 50 (63.1 ± 7.2); 50 f. | HV | T1: hospital admission T2: after few days when patients have already received beta blockers treatment T3: at hospital discharge | Mean RR; SDNN; SDANN; LF; HF; LF/HF; H; DFA α1; DFA α2; ApEn | None | Mean RR: TS-T1 < HV (p < 0.05) SDNN: TS-T1 < HV (p < 0.05); TS-T2 < TS-T3 (p < 0.05) SDANN: TS-T1 < HV (p < 0.05); TS-T2 < TS-T3 (p < 0.05) LF: TS-T1 > HV (p < 0.05); TS-T2 > TS-T3 (p < 0.05) HF: TS-T1 < HV (p < 0.05); TS-T2 < TS-T3 (p < 0.05) LF/HF: TS-T1 > HV (p < 0.01); TS-T2 > TS-T3 (p < 0.01) H: TS-T1 < HV (p < 0.001); TS-T2 < TS-T3(p < 0.001) DFA α1: TS-T1 > HV (p < 0.001); TS-T2 > TS-T3 (p < 0.001) DFA α2: TS-T1 > HV (p < 0.05); TS-T2 > TS-T3 (p < 0.01) ApEn: TS-T1 < HV (p < 0.001); TS-T2 < TS-T3 (p < 0.001) | 8 |
Lazzeroni et al., 2022*46 | 10 (69 ± 7); 9 f. | 9 (72 ± 7); 8 f. | HV | 12–24 months following the acute TS episode | SDNN; pNN50; RMSSD; VLF; LF; HF; LF/HF; SamEn; FD | 16PF; AAQ-II; STAI; BDI-II; COPE | SDNN: TS < HV (p = 0.048) pNN50: TS < HV (p = 0.003) RMSSD: TS < HV (p = 0.015) HF: TS < HV (p = 0.030) LF/HF: TS > HV (p = 0.012) FD: TS > HV (p = 0.013) | 8 |
Mayer et al., 2016**50 | 26 (64.9 ± 13.5); 26 f. | Normative data | – | Median time from the TS event to the time of investigation: 17.5 months | SDNN; SDANN; RMSSD | HADS; ESS; FSS; TICS; FPI-R; MOCA; Five point test; Stroop Task | Only descriptive data | 2 |
Norcliffe-Kaufmann et al., 2016*47 | 10 (61.7 ± 11.7); 10 f. | 10 (age not reported); 10 f. | HV | Mean time from the TS event to the time of investigation: 42.1 months | SDNN; pNN50; RMSSD; LF; HF | STAI; Somatic vigilance scale; Stroop Task; Event recall | SDNN: TS < HV (p = 0.035) pNN50: TS < HV (p = 0.014) RMSSD: TS < HV (p = 0.031) HF: TS < HV (p = 0.079) | 7 |
Ortak et al., 2009**43 | 39 (67.8 ± 10.5); 38 f. | Same group at different times | – | T1: day 1 after admission T2: day 2 after admission T3: day 3 after admission T4: 3 months after hospitalization | Mean RR; SDNN; SDNNi; SDANN; RMSSD; TI | None | SDNN: TS-T1 < TS-T3 (p = 0.041); TS-T1 < TS-T4 (p = 0.002) SDNNi: TS-T1 < TS-T3 (p = 0.050); TS-T1 < TS-T4 (p = 0.003) SDANN: TS-T1 < TS-T3 (p = 0.005); TS-T1 < TS-T4 (p < 0.001) RMSSD: TS-T1 < TS-T3 (p = 0.048); TS-T1 < TS-T4 (p = 0.050) TI: TS-T1 < TS-T4 (p = 0.020) | 3 |
Waldenborg et al., 2011**44 | 13 (70); 13 f. | Same group at different times | – | T1: within 3 days following symptom presentation T2: after 3 months | Mean RR; SDNN; SDANN; TINN; pNN50; SDSD; RMSSD; VLF; LF; HF; TF | PTSS-10; MADRS-S | SDNN: TS-T1 < TS-T2 (p = 0.008) SDANN: TS-T1 < TS-T2 (p = 0.008) | 3 |
Watson et al., 2022***49 | 12 (67.3 ± 2.9); 12 f. | 12 (66.2 ± 2.5); 12 f. | CP | Three registrations during experimental task in a follow-up visit (no time specified) T1: baseline condition T2: hyperventilation condition T3: 5 min after | SDNN | Hyperventilation induced anxiety | SDNN: increased in response to hyperventilation (p < 0.001) but no differences between cases and controls | 7 |